Please login to the form below

IQWiG

This page shows the latest IQWiG news and features for those working in and with pharma, biotech and healthcare.

Blind man's buff

In IQWIG’s words, ‘the rhetoric of novelty and innovation creates an assumption that new products are better than existing ones’. ... The IQWIG evidence tells us that our industry is wasteful of its innovative resources.

Latest news

Diurnal files adrenal insufficiency drug Alkindi in US

Care (IQWiG) concluded it had not been proven to be superior to generic hydrocortisone.
Resurgent Diurnal raises £5.4m for twin product filings

IQWiG) concluded it had not been proven to be superior to generic hydrocortisone.
Transforming access in rare diseases

From IQWiG in Germany to the HAS in France and the Pharmaceutical Benefits Advisory Committee in Australia, the reality we face is that all technology assessment organisations work in slightly different
Focus on value: A prescription for pharma

The pricing debate demands a common language to be developed
NICE backs use of AZ's Brilique as maintenance therapy

A similar verdict was reached by NICE's German counterpart IQWiG earlier this year.

More from news
Approximately 23 fully matching, plus 45 partially matching documents found.

Latest Intelligence

The gold standard of scientific evidence

PBAC appraisals, 64% of NICE appraisals and all IQWiG appraisals relied on RCT-based evidence.
Digital disruption

best patient outcomes - information that would probably come in very handy for submissions to the likes of NICE or IQWiG.
Stepping up to payer-driven market access

Combined with the demanding - and often less familiar - requirements of the GBA and IQWIG in Germany and other agencies in Europe, these changes make early understanding of the payer environment critical
The price is right?

IQWiG evaluations often focus on different patient populations from those used in the clinical trials. ... The dynamic between the G-BA and IQWiG makes pricing and reimbursement an extremely complex process.”.
Biosimilars - the same, but different?

After regulatory clarity, the focus will certainly move to health technology assessment bodies, such as Germany's IQWiG and the UK's NICE, if biosimilars' place in clinical practice is to ... For its part IQWiG has yet to assess any biosimilar products.

More from intelligence
Approximately 4 fully matching, plus 17 partially matching documents found.

Latest from PMHub

Oncology drugs under AMNOG

Usually the G-BA also seeks the advice of expert Health Technology Assessment (HTA) body IQWiG (the Institute for Quality and Efficiency in Healthcare), to determine the level of added benefit ... The G-BA and IQWiG restricted these options to therapies

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

The search for treatments for Parkinson’s disease: The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.: Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials: As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...